An observational study in Lipedema, sponsored by Istanbul Physical Medicine Rehabilitation Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Observational
Among 41 studies in Lipedema with a site in Turkey — 18 open to participants now, 19 under way, none of them phase 3. Lipedema · Turkey.
Among the 41 studies in Lipedema with a site in Turkey, this one is the 5th largest by enrollment of the 27 observational ones that give a count, is one of 9 that started in 2025, is one of 27 observational ones, and was the 17th registered.
85 studies on the registry are indexed under Lipedema; 32 are open to participants now.
This study's enrollment of 140 is above the median of 90 across 42 observational studies indexed under Lipedema.
Browse Lipedema studies →18 of the 41 studies in Lipedema with a site in Turkey are open now, in 1 country. Each count lists the studies.
Of the 19 Lipedema studies recruiting now, 3 (16%) set no upper age limit and 16 (84%) stop at 75 or younger; 0 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · female · healthy volunteers too.
The full table on the hub →41 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 9 started in 2025.
Median enrollment 37 across the 14 interventional studies, 76 across the 27 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
None of the 41 has an industry lead sponsor. The 10 most frequent:
Istanbul Physical Medicine Rehabilitation Training and Research Hospital is the lead sponsor of 123 studies on the registry; 26 are open to participants now.
Istanbul Physical Medicine Rehabilitation Training and Research Hospital has 3 studies filed under Lipedema — fewer than ten, so there is no comparison to draw.
10 of the studies in Lipedema with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878299Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyComparison of Segmental Body Composition Characteristics in Lipedema and Obesity | 2026-11-20 |
| NCT07683559Atlas UniversityExtracorporeal Shock Wave Therapy in Patients With Lipedema | 2026-12-01 |
| NCT07919574Hatice Zehra FERHATLAREffectiveness of Kinesio Taping as an Adjunct to Conservative Treatment in Women With Lipedema | 2027-01-15 |
| NCT07803926Merve SEVINC GUNDUZManual and Self-Lymphatic Drainage Combined With Exercise in Women With Lipedema | 2027-01-20 |
| NCT07468097Marmara UniversityThe Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational Study | 2027-02-01 |
Among the 41 studies in Lipedema with a site in Turkey, from their registry updates:
Women aged 18-75 years with a clinical diagnosis of lipedema and an obese control group will be included in the study. Sociodemographic and clinical data (age, height, weight, medications, etc.) of the participants will be recorded. For laboratory evaluation, fasting blood test results obtained within the last three months (including fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides) will be used. Based on these parameters, metabolic and atherogenic risk indicators such as the Triglyceride-Glucose Index (TyG), TyG-BMI, Atherogenic Index of Plasma (AIP), Atherogenic Coefficient (AC), Castelli Risk Index I (CRI-I), and Castelli Risk Index II (CRI-II) will be calculated. No additional biochemical tests will be collected from participants; analyses will be performed using existing laboratory results.
obese patients with and without lipedema
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Obese patients with lipedema
Other: No intervention
Obese patients without lipedema
Other: No intervention
No intervention
Triglyceride-Glucose Index (TyG):
The TyG index will be calculated as ln \[fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2\]. It serves as a surrogate marker for insulin resistance. Higher values indicate greater metabolic risk.
Time frame: Baseline
TyG-BMI
Calculated by multiplying the TyG index by body mass index (BMI). Higher values indicate increased insulin resistance and metabolic risk.
Time frame: Baseline
Atherogenic Index of Plasma (AIP):
Calculated as log (triglycerides / HDL-cholesterol). Higher AIP values reflect greater atherogenic risk.
Time frame: Baseline
Atherogenic Coefficient (AC):
Calculated as (total cholesterol - HDL-cholesterol) / HDL-cholesterol. Higher scores indicate higher atherogenic potential.
Time frame: Baseline
Castelli Risk Index I (CRI-I):
Calculated as total cholesterol / HDL-cholesterol. Higher values indicate increased cardiovascular risk.
Time frame: Baseline
Castelli Risk Index II (CRI-II):
Calculated as LDL-cholesterol / HDL-cholesterol. Higher scores represent greater atherogenic risk.
Time frame: Baseline
Ran from Oct 2025 to primary completion in Nov 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Physical Medicine Rehabilitation Training and Research Hospital →